133P - The mTOR kinase inhibitor AZD-2014 enhances the antitumor effects of XPO1 antagonist KPT-185 in mantle cell lymphoma

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Clinical Research
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Kazumasa Sekihara
Citation Annals of Oncology (2015) 26 (suppl_9): 37-39. 10.1093/annonc/mdv521
Authors K. Sekihara1, S. Yamamoto1, M. Kikkawa2, H. Taka2, N. Kaga2, H. Matsushita3, H. Hayashi4, M. Tanaka4, T. Miida1, M. Andreeff5, M.Y. Konopleva5, Y. Tabe1
  • 1Department Of Clinical Laboratory Medicine, Juntendo University School of Medicine, 113-8421 - Tokyo/JP
  • 2Laboratory Of Proteomics And Biomolecular Science, Biomedical Research Center, Juntendo University School of Medicine, 113-8421 - Tokyo/JP
  • 3Department Of Laboratory Medicine, Tokai University School of Medicine Isehara Campus, Isehara/JP
  • 4Support Center For Medical Research And Education, Tokai University School of Medicine Isehara Campus, Isehara/JP
  • 5Department Of Leukemia, MD Anderson Cancer Center, Houston/US



Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by the aberrant expression of several oncogenic effectors. The nuclear transporter exportin-1 (XPO1) is highly expressed in MCL andis associated with pathogenesis. The frequent activation of mTOR signaling, a central cellular metabolism regulator, is an important therapeutic target in MCL. In this study, we investigated the antitumor effects and molecular / metabolic changes of the combination of XPO1 antagonist KPT-185 with second generation mTOR kinase inhibitor AZD2014 on MCL.


Four MCL cell lines Z138, JVM2, MINO, and Jeko-1 were utilized. Cell viability was evaluated by MTT, cell counting and PI flow cytometric analysis. We then performed cDNA array, iTRAQ proteomic analysis, immunoblotting and metabolome analysis using CE-MS.


AZD2014 significantly enhanced the KPT-185-induced cell growth inhibition in the tested MCL cell lines.Transcriptomic analysis using cDNA array showed that KPT-185 / AZD-2014 affected expression of 137 genes (fold change > 2) in Jeko-1 cells. IPA analysis implicated the inhibition of STAT3 as one of the mechanistic leads. iTRAQ detected significant upregulation of glycolysis / gluconeogenesis pathways after KPT-185 treatment and KPT-185 / AZD-2014 repressed ribosomal biogenesis (KEGG analysis) with implicated activation of p53 and inhibition of p70 S6K and MYCN (IPA) in at least 2 of the 4 tested cell lines. We further found the downregulation of p-S6K and c-Myc and the upregulation of p27KIP and cleaved caspase-9 by immunoblotting. Of note, CE-MS demonstrated that the increase of lactic acid by KPT-185 was effectively reversed by AZD-2014, and that TCA cycle metabolites citric acid, succinic acid and malic acid were drastically decreased by KPT-185 / AZD-2014 combination.


Our findings indicated that inhibition of mTOR kinase enhances the antitumor effects of the XPO1 antagonist KPT-185 with effective repression of XPO1 blockage–induced glycolysis / gluconeogenesis upregulation. These findings suggest a novel promising combinatorial strategy targeting pro-survival metabolism in MCL.

Clinical trial identification


All authors have declared no conflicts of interest.